Biomarker analysis and evaluation in oncology is the product of a number of processes (including managerial, technical and interpretation steps) which need to be monitored and controlled to prevent and correct errors and guarantee a satisfactory level of quality. Several biomarkers have recently moved to clinical validation studies and successively to clinical practice without any definition of standard procedures and/or quality control (QC) schemes necessary to guarantee the reproducibility of the laboratory information. In Italy several national scientific societies and single researchers have activated -often on a pilot level -specific external quality assessment protocols, thereby potentially jeopardizing the clinical reality even further. In view of the seriousness of the problem, in 1998 the Italian Ministry of Health sponsored a National Survey Project to coordinate and standardize the procedures and to develop QC programs for the analysis of cancer biomarkers of potential clinical relevance. Twelve QC programs focused on biomarkers and concerning morphological, immunohistochemical, biochemical, molecular, and immunoenzymatic assays were coordinated and implemented. Specifically, external QC programs for the analytical phase of immunohistochemical p53, Bcl-2, c-erb-2/neu/HER2, and microvessel density determination, of morphological evaluation of tumor differentiation grade, and of molecular p53 analysis were activated for the first time within the project. Several hundreds of Italian laboratories took part in these QC programs, the results of which are available on the web site of the Network (www.cqlaboncologico.it). Financial support from the Italian Government and the National Research Council (CNR) will guarantee the pursuit of activities that will be extended to new biomarkers, to preanalytical phases of the assays, and to revision of the criteria of clinical usefulness for evaluating the cost/benefit ratio. (Int J Biol Markers, 2002; 17: 201-14)
INTRODUCTION
In the last few years the issue of the quality control (QC) of healthcare services has gained momentum in Italy as it encompasses clinical, therapeutic, diagnostic and laboratory services. In particular, the issue of quality assurance/assessment of laboratory services is quite complex because it involves different aspects including managerial and interpretation processes as well as standard operating procedures. However, in the context of QC of laboratory performance at least two major aspects can be identified: the clinical usefulness of laboratory tests and the reproducibility of performed tests.
These aspects are particularly relevant for laboratories involved in the determination of cancer biomarkers because the translational research in this area has been very intensive and provides a range of biological information of potential clinical interest for the diagnosis and treatment of different tumor types (1). Analysis of these biomarkers is very important, requiring technological fa-cilities, skilled operators and rapid scientific updating. In this context, several scientific societies and single researchers have activated specific external quality assessment (EQA) schemes -often on a pilot level -which may further jeopardize the Italian reality in this respect.
In spite of these difficulties, several biomarkers have recently moved to clinical validation studies and successively to clinical practice without any definition of standard procedures and/or QC schemes necessary to guarantee the reproducibility of the laboratory information. Furthermore, guidelines for appropriate clinical employment of each biomarker have been developed only recently. The urgent expectations of the public for new results from laboratory research that would be directly applicable to the cure of this devastating disease have contributed to the early circulation of various laboratory tests (2) .
In view of of these problems the Italian Ministry of Health (MS), the National Research Council (CNR) and the Ministry of Instruction, University and Scientific Research (MIUR) have planned a series of initiatives aimed at (i) surveying the QC programs ongoing in Italy, (ii) coordinating from a scientific and cultural point of view the activitites in this area and producing guidelines for the clinical employment of cancer biomarkers, (iii) standardizing the procedures and (iv) developing laboratory QC programs for the analysis of cancer biomarkers of validated clinical relevance and currently used in multicenter clinical protocols.
As for the last aspect, a special project was initiated in 1998 with the aim to coordinate and implement nationwide EQA programs for cancer biomarkers. The activities of the project started by involving all scientific societies that were conducting previously activated QC programs for specific biomarkers throughout the country:
the Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC), which has been running QC programs for serum markers for many years (3) ; the Società Italiana di Cinetica Cellulare Applicata e di Base (SICCAB), which has managed a nationwide QC program for 3H-thymidine labeling index (TLI) since 1989 (4) and subsequently set up a QC program for flow-cytometric S-phase fraction (FCM-S) (5) , and the Comitato Italiano Controllo Qualità del Laboratorio in Oncologia, which has been running a QC program for biochemical steroid receptor analysis for the past 10 years (6) In the present paper we briefly review the QC programs ongoing in Italy to provide information on the definition of the shared operating procedures for each QC, the procedures adopted for statistical analysis, and the characteristics and results of each activated QC program.
In addition, we provide information about the structure and content of the web site of the network.
METHODOLOGICAL CONSIDERATIONS
A summary of the QC programs ongoing in Italy at the end of 2001 is presented in Table I . Most of the re- a inquiry forms and/or identification of variability sources and establishment of protocols for analytical phase and data analysis b development of consensus-based procedures for sample selection and evaluation c a specific questionnaire was distributed among the participating laboratories d routine QC programs ported programs were activated and/or implemented within the activities of the 1998-MS project, and for each of these biomarkers a coordinating laboratory was identified that collaborated with the Statistical Unit of the project to appropriately design the study, set up the operating procedures and perform data analysis. Three of the four QC programs (Circulating Biomarkers, Hormone Receptors by Biochemical Assay and DNA Analysis by PCR Amplification), whose operating procedures, study design and data analysis were not coordinated in collaboration with the Statistical Unit of the project, had been activated previously outside the activities of the 1998-MS project.
The task of the Statistical Unit in the 1998-MS project was to develop two distinct phases. In phase I some of the methodological key points related to EQA implementation were identified and an appropriate strategy for data analysis was defined. Specific statistical tools were adopted to identify and monitor the possible sources of variability and to compare collected data. Biomarker measurement results provided by different laboratories were compared by concordance analysis using different approaches according to the type of measurement scale employed to obtain biomarker expression. In particular, the concordance correlation coefficient (ρc) (7, 8) and the graphical approach proposed by Oldham (9) and widely diffused by Altman and Bland (10, 11) were used for quantitative measurements. The weighted kappa statistic (κw) (12) was used for qualitative/ordinal and semiquantitative measurements, whereas the unweighted kappa statistic (κ) (12) was used for qualitative/nominal measurements. Moreover, phase I for the biomarker FCM-S was based on acquiring information on the major technical devices involved in its evaluation. For this purpose a specific questionnaire developed by the coordinating laboratory was distributed among the participating laboratories. For all other biomarkers, in agreement with the Statistical Unit, phase I was based on acquiring information on the analytical phase of their evaluation. Common steps characterizing the study design adopted for each biomarker were (i) sample identification and selection by the coordinating laboratory, (ii) circulation of samples among participating laboratories, (iii) biomarker evaluation by each participating laboratory and (iv) data collection and analysis. At least one observer for each participating laboratory evaluated all the samples. The between-laboratory reproducibility was evaluated by taking the data of the coordinating laboratory as the reference. In addition, for TLI and microvessel density (MVD) determination the between-laboratory reproducibility was assessed by performing all possible pairwise comparisons. Finally, for participating laboratories where more than one observer was involved in sample evaluation, the within-laboratory reproducibility was also evaluated.
In phase II, a QC scheme was developed on the basis of the previous experience and biomarker-specific proto-cols were drawn up. For each biomarker special attention was paid to the following aspects: (i) laboratory inclusion criteria, (ii) sample selection, (iii) search for reference values, (iv) definition of shared analytical and postanalytical operating procedures, (v) definition of a tolerance range for quantitative measurements, and (vi) evaluation of the within-laboratory reproducibility.
ONGOING EXTERNAL QUALITY ASSESSMENT PRO-GRAMS

S-phase fraction by flow cytometry (FCM-S)
The QC program, coordinated by the "Biomolecular Determinants of Prognosis and Prediction of Treatment Response" Unit of INTM, was activated before but implemented within the activities of the 1998-MS project (5) .
Background FCM-S is the most widely used approach for evaluation of the fraction of cells in the S-phase of the cell cycle. This approach is based on the employment of fluorochromes that specifically bind DNA; in this way the nuclear DNA content, which varies in cells during the various phases of the cell cycle, can be quantified. Such determination can be performed on isolated cellular or nuclear suspensions obtained from several types of samples including surgical specimens, fine-needle or bone marrow aspirates, and pleural or peritoneal effusions. Moreover, for solid tumors the use of formalin-fixed paraffin-embedded blocks or frozen specimens and the ad hoc improvement of analytical models have provided an easy and reproducible approach to obtain information on specimens stored for some time and obtained from different centers. FCM-S may be clinically useful in human cancers to identify high-risk patients as well as very low-risk patients, as has been shown by several studies on node-negative breast cancer and resectable colorectal cancer (13) .
Results
The questionnaire, which was completed by all participating laboratories, highlighted some critical issues in the preparation and analysis of clinical samples and in the analysis and interpretation of flow-cytometric data. The adequacy and representativity of tumor material in the sample was not always guaranteed. A high degree of variability was reported in the techniques used to stain cells or nuclei in terms of DNA binding dyes, dye concentration, and enzyme concentrations. Considerable differences were also observed in data collection in terms of the number of events recorded, chosen parameters (dot plot, histogram with/without gates) and debris/aggregation correction techniques. Moreover, a number of mathematical models to analyze DNA content histograms were proposed. These findings could explain some of the contrasting results regarding the prognostic role of FCM-S in clinically comparable studies and should be considered in future efforts to define the optimal and most reproducible mathematical approach to quantify cells in the S-phase.
Thymidine labeling index (TLI) by histoautoradiography
The QC program, coordinated by the "Biomolecular Determinants of Prognosis and Prediction of Treatment Response" Unit of INTM, was activated before but implemented within the activities of the 1998-MS project (4) .
Background
This type of quantitative measurement of cells in the S-phase of the cell cycle involves the evaluation of the fraction of cells actively synthesizing DNA, i.e., incorporating 3 H-thymidine as a specific precursor of DNA synthesis, by means of a histoautoradiographic technique. The method requires fresh tissue specimens and is characterized by high sensitivity and specificity. Histoautoradiographic evaluation of TLI has been shown to be a valid prognostic tool for several malignancies and has been utilized in prospective trials on node-negative breast cancer patients (14) (15) (16) . The reproducibility of results within and between laboratories has been partially verified in Italy through the previously implemented QC program. In addition, a kit for in vitro incubation with 3 H-thymidine and histological fixation of specimens is commercially available, contributing to the standardization of the method and to its feasibility in all healthcare institutions.
Results
For laboratories with more than one observer, concordance analysis showed a satisfactory level of withinlaboratory reproducibility (median ρc, 0.93; range, 0.84-0.98; 25 th percentile, 0.85; 75 th percentile, 0.95). For most laboratories a satisfactory level of between-laboratory reproducibility was observed when all possible pairwise comparisons were performed (median ρc, 0.87; range, 0.40-0.97; 25 th percentile, 0.73; 75 th percentile, 0.92). When the data of each laboratory were compared with the reference data of the coordinating laboratory, a satisfactory level of between-laboratory reproducibility was observed for all but one of the eight laboratories (median ρc, 0.94; range, 0.65-0.96; 25 th percentile, 0.83; 75 th percentile, 0.95).
Ki67/MIB-1 proliferative index by immunohistochemistry (IHC)
The QC program, coordinated by the Histopathology Institute of the Faculty of Medicine of the University of Ferrara, was activated before but implemented within the activities of the 1998-MS project.
Background IHC analysis of biological markers is considered highly relevant in the management of patients with invasive breast cancer. This methodological approach for the quantitative and topographic evaluation of antigens only in invasive cellular components and in increasingly frequent small tumors has been generally accepted. Many studies have evaluated the prognostic implications of Ki67/MIB-1, a proliferative index determined by IHC, and the College of American Pathologists (CAP) has recently ranked it as category 2, "factors that have been extensively studied biologically and clinically but whose importance remains to be validated in statistically robust studies" (17) .
Results
A moderate level of reproducibility was observed with values varying between 0.27 and 0.98 (median ρˆc, 0.79; 25 th percentile, 0.73; 75 th percentile, 0.90). For 18 laboratories ρc values less than 0.80 were observed.
p53 alterations
The QC program includes the evaluation of p53 expression by IHC and of p53 mutations by molecular analysis. Both programs were activated and implemented within the activities of the 1998-MS project, although the QC for p53 mutations was not concerted with the Statistical Unit. The projects were coordinated by the "Biomolecular Determinants of Prognosis and Prediction of Treatment Response" Unit of INTM and by the Oncology Department of the University of Pisa, respectively.
Background
The p53 tumor suppressor gene is one of the most frequently altered genes in human malignancies. It is involved in the control of cell cycle progression, apoptosis and DNA repair mechanisms (18) . p53 mutations are among the most frequently detected genetic changes in human cancer. Tumors characterized by mutations within the p53 gene are usually more aggressive and their sensitivity to various antineoplastic drugs seems to depend on specific types of p53 mutations. On the basis of these observations several gene therapy protocols with wild-type p53 have been activated (19) and it is general-ly accepted that p53 mutations are clinically relevant in different types of human tumors. p53 alterations are detectable at the gene level by mutational analysis and direct sequencing and at the protein level by Western blotting and IHC.
Assessment of p53 expression by IHC is the most common technique to detect p53 alterations. Findings that have emerged from retrospective studies provide evidence for an association between p53 alterations and clinical outcome, specifically in terms of staging, prognosis and prediction of treatment response in malignancies such as colorectal and breast cancer (20) . Conflicting data in the literature for each of these aspects suggest that this biomarker has not been sufficiently validated for routine clinical practice.
The single-strand conformational polymorphism (SS-CP) and the denaturant-gradient-gel electrophoresis (DGGE) assays are the most frequently used techniques for the detection of p53 mutations. The sensitivity and specificity of these two techniques are still under investigation; however, the reported lower sensitivity of the SS-CP assay may reflect some as yet undefined methodological difficulties (21) . Nevertheless, SSCP analysis is more widely used than DGGE because it is simpler to perform.
p53 expression by IHC: study design and results
Eleven out of 18 laboratories systematically underestimated the percentage of immunoreactive cells and one laboratory reported a higher fraction of positive cells than the coordinating laboratory. Furthermore, for two laboratories the number of immunoreactive cells was smaller for weakly p53 expressing and greater for strongly p53 expressing tumors compared to the data of the coordinating laboratory. For three laboratories no systematic trend was observed. When the pattern of between-laboratory reproducibility was explored by dichotomizing the measures as negative or positive (according to a cutoff value of 5% of immunoreactive cells), there was perfect agreement between the coordinating laboratory and all participating laboratories (κ = 1).
p53 mutations by molecular analysis: study design and results
In an attempt to overcome the above-mentioned technical problems and render the results of different laboratories more homogeneous, an EQA program for p53 mutations detected by SSCP or DGGE involving 15 Italian laboratories was activated: 12 laboratories were equipped for SSCP and three for DGGE analysis. In phase I the protocols for molecular analysis were not standardized and DNA samples extracted from 15 human breast cancers with known p53 mutations were sent for analysis. To date, results have been obtained from 11 centers: in eight cases the screening method used was the SSCP assay and in three cases the DGGE assay. Results were concordant in more than 90% of cases (91% and 93% for the SSCP and DGGE methods, respectively). Discordant data were attributable to protocol differences. These results suggest that the two techniques for the detection of p53 mutations are both highly reliable. An accurate analysis of the physicochemical parameters influencing the results is in progress. In phase II of the QC program the use of a standardized protocol will further improve the sensitivity and specificity of these assays.
Bcl-2 expression by IHC
The QC program, coordinated by the Histopathology Laboratory of IRE of Rome, was activated and implemented within the activities of the 1998-MS project.
Background
The Bcl-2 family of proteins are key regulators of programmed cell death or apoptosis, which is implicated in many human diseases and especially in cancer. Alterations in apoptotic pathways may result in resistance to drugs and radiation. Such alterations could theoretically predict chemoresistance and could represent new treatment targets (22) . Several clinical studies have evaluated the role of Bcl-2 in the response to anticancer therapy and in disease outcome in several large series of patients with colon or breast cancer, but the results obtained so far are rather controversial (23, 24) . In this context the standardization of Bcl-2 immunostaining and the reproducibility of biomarker evaluation among researchers play a pivotal role in the assessment of the prognostic and predictive value of Bcl-2 in patients with solid tumors.
Results
Concordance analysis showed a moderate level of between-laboratory reproducibility with κw values ranging from 0.66 to 0.93 (median κw, 0.81; 25 th percentile, 0.74; 75 th percentile, 0.86). When only samples classified by the coordinating laboratory as having a percentage of immunopositive cells different from 0 were considered, an unsatisfactory level of agreement was observed for all 12 participating laboratories (median κw, 0.32; range, 0.11-0.65; 25 th percentile, 0.24; 75 th percentile, 0.42).
HER-2 expression by IHC
The QC program, coordinated by the Biological Laboratory of the Medical Oncology department of IOR of Forlì, was activated and implemented within the activities of the 1998-MS project.
Background
The receptor-2 of the human epidermal growth factor family is overexpressed in 20-30% of breast cancers and in most cases reflects the amplification of the protooncogene HER-2 (25) . Literature sources provide contradictory results about the potential relevance of HER-2 expression as an indicator of sensitivity or resistance to specific systemic therapy in patients with solid tumors, in particular breast cancer (26, 27) . This discordance may be due to the heterogeneity of the case series and to the lack of standardization of preanalytical and analytical procedures.
Results
Concordance analysis showed a fairly good level of between-laboratory reproducibility with κ w values ranging from 0.78 to 0.98 (median κw, 0.94; 25 th percentile, 0.93; 75 th percentile, 0.97) and from 0.71 to 0.95 (median κ w, 0.90; 25 th percentile, 0.87; 75 th percentile, 0.93) for the percentage of immunopositive cells (semiquantitative measurement) and staining intensity (qualitative measurement), respectively. In addition, a low level of agreement was observed for all 14 participating laboratories when only samples classified by the coordinating laboratory as having a percentage of immunopositive cells different from 0 and 100% were taken into consideration (median κw, 0.89; range, 0.57-0.96; 25 th percentile, 0.89; 75 th percentile, 0.94).
Steroid receptors
The QC program includes the evaluation of steroid receptors by IHC and by biochemical assay. The former, coordinated by the Histopathology Institute of the Faculty of Medicine of the University of Ferrara, was activated before but implemented within the activities of the 1998-MS project. The latter, coordinated by the Regional Center for the Study of Biological Markers of Malignancy in Venice within an ad hoc EORTC program, was activated before and managed outside the 1998-MS project.
Background
Estrogens influence the normal proliferation, differentiation and physiology of breast tissue, as well as the pathogenesis and progression of breast cancer. These physiological effects of estrogens are mediated by a specific estrogen receptor (ER). Approximately 50-60% of ER-positive breast cancer patients respond to endocrine therapy, as opposed to only 5-10% of patients with ERnegative tumors. Measurement of the progesterone receptor (PgR), which is an estrogen-regulated protein, has been shown to improve the discrimination between hormone-sensitive and hormone-resistant breast can-cers. The availability of information about ER and PgR in a number of clinical trials on endocrine treatment of breast cancer has demonstrated that their determination is mandatory to predict responsiveness to hormone manipulations (28) .
For more than 20 years the reference method for the determination of ER and PgR in tissue samples has been the dextran-coated radioligand binding assay (LBA). Full standardization of the assay, continuous monitoring of the laboratory procedures, and a 23year-old quality assurance scheme, coordinated both at a national and European level (6), could be the template for all other biomarkers that are candidates for clinical use. The relevance of the IHC technique for quantitative/topographic evaluation of biological markers such as ER and PgR only in the invasive cellular components and in increasingly frequent small tumors has been generally accepted (29, 30) . Recently, the CAP ranked ER and PgR as category 1, "factors proven to be useful in clinical patient management" (17) . The sensitivity and specificity of the different approaches to determine ER/PgR are beyond the aim of the present study.
ER/PgR expression by IHC: results
ER: A rather unsatisfactory level of between-laboratory reproducibility was observed, with ρc values ranging between 0.09 and 0.86 (median ρc 0.56; 25 th percentile, 0.49; 75 th percentile, 0.68). For all but one of the 36 laboratories ρc values below 0.80 were observed.
PgR: A good level of between-laboratory reproducibility was observed for most centers, with ρ c values ranging between 0.04 and 0.99 (median ρ c, 0.92; 25 th percentile, 0.83; 75 th percentile, 0.95). For seven of the 36 laboratories ρ c values below 0.80 were observed.
ER/PgR by biochemical assay: study design and results
The EQA program for ER and PgR has been active since 1979 and is coordinated by the Receptors and Biomarkers Group of the EORTC. The program is aimed at monitoring both between-and within-laboratory variability in biomarker determination.
The within-laboratory variability was assessed by two-monthly analysis of 12 vials of lyophilized human uterine tissue with the addition of recombinant ER, distributed on a yearly basis by the central laboratory in The Netherlands. With regard to the between-laboratory interassay variability, a set of frozen cytosol samples obtained from calf uterine tissue and prepared by the Italian Reference Center was distributed to all participating laboratories for assessment along with the routine samples; this would allow evaluation of both between-and within-assay variations. The assay proce-dures performed in the different laboratories participating in the program were also monitored by means of a questionnaire focusing on both significant and minor changes in the assay method currently used in each laboratory. The centers were requested to send back a set of their data (crude counting results of a Scatchard plot) and the final result obtained using a routine algorithm.
The results of EQA showed an intra-assay variation of approximately 5-15% and an interassay variation ranging from 25% to 40%. In view of the complexity of this methodology, the analytical reliability within each individual center was considered adequate. Furthermore, all of the 14 participating laboratories completed the questionnaire, performed the calculation and sent back the whole documentation within three months.
Preanalytical and analytical protocol variations. The results of our survey showed that almost all the laboratories adopted some changes in their analytical methods; this means that, in spite of the recommendations of the EORTC, virtually every laboratory used a self-tailored method. However, according to previous evaluations of every assay step, changes in the assay protocol are within acceptable ranges of tolerance.
Calculation protocol. Calculation methods were also re-evaluated, showing that the differences observed between the various methods did not influence withinlaboratory variations by more than 10%.
In conclusion, the variability observed in the EQA does not appear to be related to the spontaneous variations in the assay method that every laboratory adopts when using in-house methods, or to the computation of the results by means of different algorithms. These findings support the need to standardize biomarker determination, at least when evaluating biomarkers in multicenter clinical trials to avoid biases that cannot be foreseen or controlled.
In terms of future developments, several new biomarkers will soon be utilized in clinical practice to improve the prediction of hormone response; some of the candidates are ERβ, coactivators and corepressors. These biomarkers will almost certainly be measured with in-house methods. The EQA experience of ER and PgR determination, planned and carried out according to EORTC recommendations, could represent a valuable template to standardize and monitor the use of other biomarkers for evaluation of the endocrine regulation of breast cancer.
Histopathological grading
The QC program, coordinated by the Histopathology Service of the Morgagni-Pierantoni Hospital of Forlì, was activated and implemented within the activities of the 1998-MS project.
Background
A fundamental feature of histopathology is that the morphological appearance of neoplastic cells can be related to the degree of tumor differentiation. In breast cancer, a large number of studies have been carried out to determine which morphological criteria may correctly assess tumor grade (31) . The most frequently used method is the Nottingham method, which bases the assessment of tumor grade on three morphological features: tubule formation, nuclear pleomorphism and mitotic count (32) . As demonstrated by Elston et al (33) , this score appears to be an independent prognostic factor based on a large number of patients with long-term follow-up.
Results
In all but one of the participating laboratories, two observers evaluated all the samples. Overall, concordance analysis showed a fairly good level of within-laboratory reproducibility with κw values ranging between 0.34 and 1.00 (median κw, 0.90; 25 th percentile, 0.75; 75 th percentile, 0.95). In this case κw values greater than 0.80 were observed for five out of 10 laboratories. When the data of the coordinating laboratory were taken as the reference, concordance analysis showed an unsatisfactory level (κ w < 0.80) of between-laboratory reproducibility for all but one of the participating laboratories. Finally, with regard to the within-laboratory reproducibility of each of the variables scored to obtain grading classification, nuclear pleomorphism (median κw, 0.36; range, 0.19-1.00; 25 th percentile, 0.63; 75 th percentile, 0.75) and mitotic count (median κw, 0.77; range, 0.29-0.94; 25 th percentile, 0.62; 75 th percentile, 0.83) appeared to be unsatisfactory in comparison with tubule formation (median κ w, 0.81; range, 0.31-1.00; 25 th percentile, 0.62; 75 th percentile, 0.92).
Microvessel density (MVD)
The QC program, coordinated by the Biological Laboratory of the Department of Medical Oncology of IOR of Forlì, was activated and implemented within the activities of the 1998-MS project.
Background
It has been demonstrated recently that the growth and proliferation of tumor cells, as well as metastatic spread, are preceded and enhanced by the formation of new blood vessels (34) . The prognostic value of angiogenesis, expressed as MVD, has been assessed in patients with different tumor types (melanoma, lung cancer, prostate cancer, etc.); studies on large series of patients with node-negative breast cancer have produced controversial results in this respect (35) . Several antiangio-genic compounds have been synthesized which are able to interfere in vivo with this biological capacity of the tumor (36) . Since neovascularization could become a target for molecular therapeutic approaches, there is a clear need to evaluate MVD in tumors.
Results
The data of each laboratory were compared with those of the coordinating laboratory and concordance analysis showed an unsatisfactory level of betweenlaboratory reproducibility with ρ c values ranging from -0.01 to 0.67 (median ρc, 0.41; 25 th percentile, 0.34; 75 th percentile, 0.57) and from 0.09 to 0.77 (median ρ c 0.54; 25 th percentile, 0.43; 75 th percentile, 0.63) for the maximum and mean MVD, respectively. For all seven centers values less than 0.80 were observed. The unsatisfactory degree of between-laboratory reproducibility was confirmed by comparing the data of each laboratory with those of the coordinating laboratory for both maximum (median ρ c, 0.41; range, 0.21-0.67; 25 th percentile; 0.34; 75 th percentile, 0.57) and mean (median ρc, 0.54; range, 0.27-0.72; 25 th percentile, 0.43; 75 th percentile, 0.63) MVD. Moreover, the within-laboratory reproducibility appears to be unsatisfactory for both maximum (ρ c = 0.62) and mean (ρ c = 0.72) MVD also for the coordinating laboratory where two observers evaluated all the samples.
Circulating biomarkers
The QC program Oncocheck, sponsored by the SIBioC and coordinated by Cis Diagnostici SpA (Milan), was activated before and managed outside the 1998-MS project.
Background
The measurement of circulating tumor markers has been one of the most rapidly developing areas of research in laboratory medicine in recent years. These markers are already available in clinical practice for diagnosis and treatment monitoring of several diseases (37) . However, despite the rapid expansion and great interest of these markers, there are some critical issues that need to be addressed in order to improve the clinical usefulness of tumor markers in patient management. Such issues concern the preanalytical, analytical and postanalytical phases. Loss of reproducibility of the different phases strongly affects the clinical effectiveness of the biological information (38) . Specific QC programs have been active for a long time to guarantee the reliability and accuracy of circulating tumor marker determination. These are specifically related to the need to standardize the procedures of all phases of circulating biomarker analysis.
Study design
In close collaboration with the SIBioC, the Regional Center for the Study of Biological Markers of Malignancy of Venice and the Department of Laboratory Medicine of the University Hospital of Padua developed and implemented a program aimed to: (i) assess and improve the quality of the assays for circulating tumor markers, establishing analytical quality specifications according to the hierarchy of models proposed and accepted at the Stockholm Consensus Conference promoted by the WHO and IFCC (39) ; (ii) evaluate and improve the quality of reports by standardizing criteria that would enable clinicians to achieve more accurate interpretation and better utilization of laboratory information (40) .
Results
The efforts were aimed at promoting the efficiency and effectiveness of EQA schemes to improve the quality of laboratory testing, especially in the field of tumor markers and in all accreditation/certification programs for medical laboratories (41) . After collecting information from a large number of laboratories in different regions of Italy, we recommended QC criteria to limit pre-, intra-and postanalytical errors and to improve the utilization of laboratory tests (38) . The QC program will be extended to as many Italian regions as possible in order to achieve the accreditation of EQA schemes and to improve the quality of laboratory reports and the determination of circulating tumor markers.
DNA analysis by PCR amplification
The present QC program, coordinated by the Clinical Biochemistry Laboratory of the Clinical Physiopathology Department of the University of Florence, was activated before and managed outside the 1998-MS project.
Background
In spite of the variety of possible applications of PCR-based molecular techniques, EQA programs to date have been limited to a few tests assessing their clinical value. EQA programs should be directed at evaluating the analytical aspects common to most PCR-based molecular tests (42) . The present EQA program for DNA extraction, amplification and post-PCR analysis planned three levels of quality control: (i) DNA extraction (quality and quantity); (ii) PCR performance (specificity and efficiency); (iii) interpretation of the results after electrophoresis.
Study design
In 1999 and 2001 two batches of reagents were sent to 35 and 64 laboratories, respectively, throughout Italy. The control materials contained (i) one reference DNA sample (control) obtained from normal human leukocytes with, in addition to the natural target of amplification, another target with a different bp size but amplified by the same primers; (ii) one sample of whole blood (sample); (iii) three standards, with different DNA concentrations and 260/280 nm ratios; (iv) three pairs of primers; (v) instructions for PCR amplification.
The following procedures were recommended: (i) DNA extraction from blood samples with the currently used procedure; (ii) DNA quality and quantity estimation in control and standard DNA using conventional procedures; (iii) amplification, in duplicate, of sample and control with the primer pairs provided; (iv) evaluation of the number and size of PCR products, after conventional gel electrophoresis, in one of each duplicate; (v) delivery of the other duplicate samples to the program coordinators for simultaneous and overall evaluation of all amplified samples.
Numerical data on the measurement of DNA quantity and quality for each provided sample were collected from each participant.
Results
The post-PCR samples were also checked simultaneously after gel electrophoresis to determine the number and size of the bands and measure, by means of image analysis systems, the intensity of PCR products. The expected findings (number and exact size of templates) were returned to each laboratory to check the specificity of their results. A global estimation of PCR amplification efficiency was based on the mean densitometric value of each PCR product. Analysis of the data collected showed reasonable homogeneity with regard to DNA extraction but great variability in the efficiency and specificity of amplification procedures and analysis of results. These preliminary data seem to confirm the validity of this EQA program. A new batch of reagents will be made available in the next few months for phase III of the program.
THE WEB SITE OF THE ITALIAN NETWORK FOR CAN-CER BIOMARKER QUALITY ASSESSMENT
One of the main objectives of the MS project was to propagate the practice of QC in cancer biomarkers throughout the country. The project committee therefore implemented a virtual network with the specific aim to improve the communication among operators and to facilitate the contacts with the project leaders outside the network.
The web site www.cqlaboncologico.it describes in detail the QC schemes activated in Italy, the operating procedures, and the results obtained within the QC rounds; it also provides a list of laboratories participating in each QC program and a short description of each biomarker with an updated bibliography. Patient data are displayed in agreement with the current privacy legislation.
The web site has had a strong impact on the scientif- 
Number of contacts
ic community in Italy. The data presented in Figure 1 show that it has been visited 7695 times in 90 days, with 68% of visitors from European countries and 23% from the US. The most frequently visited pages (Fig. 2) were the technical pages on biomarkers (22% of contacts) and those related to administrative and legislation problems concerning laboratory practice (14%); this reflects the increasing interest of operators in this aspect of their activity. Finally, the site is provided with links to web sites of international organizations involved in QC programs.
CONCLUSIONS AND FUTURE PROSPECTS
The 1998-MS project has allowed us to reach a number of important goals. First of all, a survey of the national activities of several scientific societies and researchers in the area of QC has been performed, facilitating the exchange of information, methodologies, etc. In addition, • several new QC schemes have been implemented;
• specific operating procedures have been designed for several QC programs; • specific analytical methods have been developed; • a multifunctional web site has been created.
All these results have been obtained also by discussing various issues on an international level with experts from other European countries (43) . An international meeting held in September 2001 in Bari (Italy) concluded the program.
On the basis of these results MS, CNR and MIUR have recently cofunded a new project, whose endpoints will be (i) the requirement of certified QC programs for tumor biomarkers; (ii) the activation of high-quality QC programs throughout the country; (iii) the assessment of these procedures in clinical validation studies. Lastly, updated guidelines for the clinical use of these biomarkers will be prepared by a scientific committee representing clinical and experimental expertise. 
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